Browse Category

NASDAQ:DXCM 7 July 2025 - 15 February 2026

Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

The Health Care Select Sector SPDR Fund (XLV) rose 1.1% to $157.67 Friday, led by Dexcom’s 7.6% jump and Moderna’s 5.3% gain after earnings. Dexcom beat Q4 estimates and reiterated its 2026 outlook, while Moderna forecast up to 10% revenue growth, citing overseas markets. Broader markets saw tech lag as inflation data cooled. U.S. exchanges close Monday for Presidents Day.
DexCom stock jumps in premarket after early Q4 sales and 2026 outlook; what DXCM investors watch next

DexCom stock jumps in premarket after early Q4 sales and 2026 outlook; what DXCM investors watch next

DexCom shares rose about 5% premarket Tuesday after the company reported preliminary Q4 revenue of $1.26 billion, up 13% year over year, and issued 2026 guidance above prior expectations. U.S. sales reached $892 million, with international revenue at $368 million. The company reaffirmed 2025 margin targets and raised 2026 goals. Barclays downgraded DexCom, citing competitive pressures despite strong sales.
Accenture stock jumps 4% on fresh AI moves: Profitmind deal, Faculty buy plan

Accenture stock jumps 4% on fresh AI moves: Profitmind deal, Faculty buy plan

Accenture shares climbed 4.1% to $285.18 Thursday after the company announced a new AI partnership with Profitmind and a deal to buy UK-based Faculty. The Faculty acquisition, which adds over 400 staff, aims to expand Accenture’s “safe AI” offerings. Analyst Surinder Thind raised his price target to $290. General counsel Joel Unruch sold 1,332 shares at $275 each in a prearranged trade.
Global Wearable Health Tech News – June and July 2025

Global Wearable Health Tech News – June and July 2025

Biobeat’s cuffless vital-sign patch received FDA clearance and CE marking for remote hospital monitoring. PharmaSens and SiBionics unveiled the niia™ signature patch, combining a continuous glucose monitor and insulin pump, at ADA 2025. Fasikl’s Felix NeuroAI Wristband became the first FDA-cleared neuromodulation wearable for essential tremor. U.S. HHS Secretary RFK Jr. launched the MAHA initiative for nationwide wearable adoption.
Go toTop